Physician profile
Jonathan Gitter
NPI 1811082902
$4,198.93
in general payments reported to CMS, 2019-2025
31 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $573 · 2021: $722 · 2022: $524 · 2023: $707 · 2024: $671 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.72 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $809.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $671.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $613.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $380.50 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $324.63 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $183.94 | 2019-2023 | |
| Daiichi Sankyo INC. | $137.77 | 2020-2021 | |
| Pfizer INC. | $120.75 | 2020-2025 | |
| Exact Sciences Corporation | $103.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $94.68 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.72 | 2021-2022 | |
| Electronic Waveform Lab, INC. | $66.97 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $60.92 | 2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $53.96 | 2025 | |
| Optinose US, INC. | $52.02 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.86 | 2025 | Krystexxa |
| Allergan, INC. | $49.78 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $44.05 | 2022-2023 | Rexulti |
| Tactile Systems Technology INC | $40.94 | 2019-2023 | Entre Plus, Flexitouch Plus |
| Abbott Laboratories | $33.59 | 2022 | |
| Gilead Sciences, INC. | $32.07 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2025 | Vpriv |
| Almatica Pharma LLC | $25.31 | 2021 | |
| Philips North America LLC | $23.31 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Nevro Corp. | $20.95 | 2022 | |
| Phadia US INC. | $20.78 | 2021 | |
| Horizon Therapeutics Plc | $17.80 | 2023 | Krystexxa |
| Endo Pharmaceuticals INC. | $16.96 | 2019 | |
| Genzyme Corporation | $16.56 | 2023 | |
| Esperion Therapeutics, INC. | $14.07 | 2021 | |
| International Rehabilitative Sciences, INC | $13.54 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gitter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.